PGL4001

Asset

Selective progesterone receptor modulator

Stage: Phase 3
Modality: Small molecule
Target: PGR; 1
Indication: 159
Trials: 1
Developer

Indications

1

Uterine fibroid
Phase 3, Completed, NCT01252069, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners1
Trials159
Evidence for its targets2
Competitors6
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 2 sources